Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 15:04 |
Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dong…
|
English | 11.1 KB | ||
| 2025-11-06 07:09 |
Heidelberg Pharmas Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Tr…
|
English | 12.9 KB | ||
| 2025-11-03 10:07 |
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at…
|
English | 13.7 KB | ||
| 2025-10-23 07:57 |
Heidelberg Pharmas Lead ADC Candidate HDP-101 Granted Fast Track Designation by…
|
English | 11.4 KB | ||
| 2025-10-13 14:35 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | ||
| 2025-10-09 07:03 |
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
|
English | 31.8 KB | ||
| 2025-10-09 00:00 |
Quartalsfinanzbericht
|
German | 70.8 KB | ||
| 2025-10-09 00:00 |
Q3 statement / Q3 financial report 2024/2025
|
English | 336.4 KB | ||
| 2025-10-06 15:58 |
Heidelberg Pharma AG Announces Updated Guidance
|
English | 10.7 KB | ||
| 2025-09-25 10:51 |
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC…
|
English | 13.5 KB | ||
| 2025-09-04 09:46 |
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to…
|
English | 12.2 KB | ||
| 2025-08-28 03:50 |
Heidelberg Pharmas Partner Telix Pharmaceuticals Gives Regulatory Update for it…
|
English | 11.8 KB | ||
| 2025-07-31 17:14 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | ||
| 2025-07-31 00:00 |
Datum:31.07.2025
|
German | 9.2 KB | ||
| 2025-07-31 00:00 |
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
|
German | 5.9 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
